FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022221517> ?p ?o ?g. }

• W2022221517 endingPage "S811" @default.
• W2022221517 startingPage "S811" @default.
• W2022221517 abstract "Selenium in the form of selenized yeast was reported by Clark et al. to have possible lung cancer chemopreventive benefits based on a secondary observation emanating from a large skin cancer prevention trial. (JAMA 1996; 276: 1957-1963). Since that time, epidemiologic, in vitro, and therapeutic research studies have continued to support the hypothesis that non-toxic selenium supplementation may decrease the risk of aerodigestive cancer in persons at high risk, e.g., those with resected bronchogenic cancer. Since October 2000, the Eastern Cooperative Oncology Group (ECOG) with support from the National Cancer Institute Division of Cancer Prevention (NCI-DCP) has been conducting an intergroup double blind placebo controlled trial using 200 micrograms of Selenium in a 2:1 randomization versus placebo. Eligibility requirements include completely resected Stage I (T1 or T2, N0) non-small cell cancer of the lung with a minimum of 1 negative mediastinal lymph node. Pts must have normal level of selenium / vitamin intake, satisfactory liver function, a negative chest x-ray and no other evidence of recurrence. Enrollment is allowed from 6 to 36 months post thoracotomy. A four wk run-in period is required during which pts must take at least 75% of the study drug to document compliance. As of March 7, 2007, 1268 pts have enrolled out of a projected total study size of 1960 participants. Treatment is for 48 months. Study endpoints include cancer recurrence, incidence of second primary lung tumors (SPTs), and/or toxicity. Treatment appears to be extremely well tolerated in this study. As of December 2006, a total of 363 patients on randomized step have reported treatment-related toxicities. Only six of them reported toxicities of grade 3 or higher as a worst toxicity. 133 grade 3, 4, or 5 severe adverse events have been reported with no difference between study drug and placebo. A total of six cooperative groups are participating in this ambitious project. Selenium appears to be very well tolerated in this setting. Accrual is projected to continue until 1960 pts have enrolled or until 90 SPTs have occurred." @default.
• W2022221517 created "2016-06-24" @default.
• W2022221517 creator A5008786567 @default.
• W2022221517 creator A5026555468 @default.
• W2022221517 creator A5040709213 @default.
• W2022221517 creator A5052461112 @default.
• W2022221517 creator A5057026118 @default.
• W2022221517 creator A5058476987 @default.
• W2022221517 creator A5060104863 @default.
• W2022221517 creator A5070688651 @default.
• W2022221517 creator A5074182063 @default.
• W2022221517 creator A5075810361 @default.
• W2022221517 date "2007-08-01" @default.
• W2022221517 modified "2023-09-29" @default.
• W2022221517 title "P1-185: Progress report: Eastern Cooperative Oncology Group (ECOG) E5597, an intergroup phase iii randomized double blind chemoprevention trial of selenium supplementation in resected stage i non small cell lung cancer" @default.
• W2022221517 doi "https://doi.org/10.1097/01.jto.0000284283.54821.a1" @default.
• W2022221517 hasPublicationYear "2007" @default.
• W2022221517 type Work @default.
• W2022221517 sameAs 2022221517 @default.
• W2022221517 citedByCount "0" @default.
• W2022221517 crossrefType "journal-article" @default.
• W2022221517 hasAuthorship W2022221517A5008786567 @default.
• W2022221517 hasAuthorship W2022221517A5026555468 @default.
• W2022221517 hasAuthorship W2022221517A5040709213 @default.
• W2022221517 hasAuthorship W2022221517A5052461112 @default.
• W2022221517 hasAuthorship W2022221517A5057026118 @default.
• W2022221517 hasAuthorship W2022221517A5058476987 @default.
• W2022221517 hasAuthorship W2022221517A5060104863 @default.
• W2022221517 hasAuthorship W2022221517A5070688651 @default.
• W2022221517 hasAuthorship W2022221517A5074182063 @default.
• W2022221517 hasAuthorship W2022221517A5075810361 @default.
• W2022221517 hasBestOaLocation W20222215171 @default.
• W2022221517 hasConcept C121608353 @default.
• W2022221517 hasConcept C126322002 @default.
• W2022221517 hasConcept C141071460 @default.
• W2022221517 hasConcept C142724271 @default.
• W2022221517 hasConcept C143998085 @default.
• W2022221517 hasConcept C204787440 @default.
• W2022221517 hasConcept C27081682 @default.
• W2022221517 hasConcept C2776256026 @default.
• W2022221517 hasConcept C71924100 @default.
• W2022221517 hasConcept C90924648 @default.
• W2022221517 hasConceptScore W2022221517C121608353 @default.
• W2022221517 hasConceptScore W2022221517C126322002 @default.
• W2022221517 hasConceptScore W2022221517C141071460 @default.
• W2022221517 hasConceptScore W2022221517C142724271 @default.
• W2022221517 hasConceptScore W2022221517C143998085 @default.
• W2022221517 hasConceptScore W2022221517C204787440 @default.
• W2022221517 hasConceptScore W2022221517C27081682 @default.
• W2022221517 hasConceptScore W2022221517C2776256026 @default.
• W2022221517 hasConceptScore W2022221517C71924100 @default.
• W2022221517 hasConceptScore W2022221517C90924648 @default.
• W2022221517 hasIssue "8" @default.
• W2022221517 hasLocation W20222215171 @default.
• W2022221517 hasOpenAccess W2022221517 @default.
• W2022221517 hasPrimaryLocation W20222215171 @default.
• W2022221517 hasRelatedWork W2002120878 @default.
• W2022221517 hasRelatedWork W2003938723 @default.
• W2022221517 hasRelatedWork W2047967234 @default.
• W2022221517 hasRelatedWork W2118496982 @default.
• W2022221517 hasRelatedWork W2364998975 @default.
• W2022221517 hasRelatedWork W2369162477 @default.
• W2022221517 hasRelatedWork W2439875401 @default.
• W2022221517 hasRelatedWork W4238867864 @default.
• W2022221517 hasRelatedWork W2519357708 @default.
• W2022221517 hasRelatedWork W2525756941 @default.
• W2022221517 hasVolume "2" @default.
• W2022221517 isParatext "false" @default.
• W2022221517 isRetracted "false" @default.
• W2022221517 magId "2022221517" @default.
• W2022221517 workType "article" @default.